Spyre Therapeutics (SYRE) R&D In Process (2023)
Spyre Therapeutics' R&D In Process history spans 1 years, with the latest figure at -$298000.0 for Q3 2023.
- For Q3 2023, R&D In Process changed N/A year-over-year to -$298000.0; the TTM value through Sep 2024 reached -$298000.0, down 100.23%, while the annual FY2023 figure was $130.2 million, N/A changed from the prior year.
- R&D In Process reached -$298000.0 in Q3 2023 per SYRE's latest filing, down from $130.5 million in the prior quarter.
- In the past five years, R&D In Process ranged from a high of $130.5 million in Q2 2023 to a low of -$298000.0 in Q3 2023.